About Mind.Px™ from Mindera Health™
Mindera Health™ Signs Contract with Nationwide Provider Network MediNcrease™
October 03, 2023 10:00 ET | Mindera Health
San Diego, CA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Mindera Health™ today announces the signing of a network provider contract with MediNcrease Health Plans, a national provider network and provider...
Ron Rocca
Mindera Health™ Announces Change to Executive Leadership Team
May 11, 2023 15:57 ET | Mindera Health
San Diego, CA, May 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has announced a change in its executive...
About Mind.Px™
Mindera Health™ Announces Coverage with Evidence Project with Highmark, Inc. to Advance Moderate-to-Severe Psoriasis Patient Care and Reduce Specialty Drug Spending
April 11, 2023 09:00 ET | Mindera Health
San Diego, CA, April 11, 2023 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of Mind.Px, the first realization of precision medicine in psoriasis, has initiated a coverage with evidence project...
Mindera Health™ Appoints Linh H. Le as Chief Financial Officer and Chief Operating Officer
Mindera Health™ Appoints Linh H. Le as Chief Financial Officer and Chief Operating Officer
March 14, 2023 08:00 ET | Mindera Health
San Diego, CA, March 14, 2023 (GLOBE NEWSWIRE) -- Mindera Health, the developer of Mind.Px™, the first realization of precision medicine in psoriasis, has appointed Mr. Linh H. Le as Chief Financial...
By Using Mind.Px, Patients Achieve PASI75 Faster than Treatment-as-Usual Cohort
Interim Results of MATCH Study Demonstrate Improved Decision Making and Clinical Outcomes When Using Mind.Px™ to Determine Biologic Drug Class for Psoriasis Patients
October 20, 2022 08:00 ET | Mindera Health
San Diego, CA, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interim clinical utility and patient outcomes data regarding Mindera Health’s Mind.Px™ test from the ongoing MATCH study were recently presented at...
Mindera Health™ Laun
Mindera Health™ Launches Pilot with National Health Insurance Company to Improve Management of Moderate-To-Severe Psoriasis Patients Through Precision Medicine
April 28, 2022 08:00 ET | Mindera Health
San Diego, CA, April 28, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, the developer of the groundbreaking Dermal Intelligence™ platform - the first realization of precision medicine in psoriasis, has...
Mindera Health™ Appoints Ted St. Martin as Chief Financial Officer
Mindera Health™ Appoints Ted St. Martin as Chief Financial Officer
March 10, 2022 08:00 ET | Mindera Health
San Diego, CA, March 10, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of precision medicine in psoriasis, ...
Mindera Health™ Appoints Deborah L. Rice-Johnson to its Board of Directors
Mindera Health™ Appoints Deborah L. Rice-Johnson to its Board of Directors
March 01, 2022 08:00 ET | Mindera Health
San Diego, CA, March 01, 2022 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in...
Mindera Health and WellDyne Enter Definitive Agreement for use of Mind.Px
Mindera Health™ and WellDyne announce a definitive agreement to improve management of moderate-to-severe psoriasis patients
January 04, 2022 11:00 ET | Mindera Health
SAN DIEGO, CA and LAKELAND, FL, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Mindera Health™ and WellDyne have entered into a definitive agreement to improve the management of psoriasis patients with moderate...
Mind.Px is the flagship test of Mindera Health.
Mindera Health™ announces publication of positive results from STAMP-1 and STAMP-2 studies
November 16, 2021 11:30 ET | Mindera Health
San Diego, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Mindera Health™, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis,...